GEAP202416578A - Methods of weight loss and preserving skeletal muscle mass - Google Patents

Methods of weight loss and preserving skeletal muscle mass

Info

Publication number
GEAP202416578A
GEAP202416578A GEAP202416578A GEAP2024016578A GEAP202416578A GE AP202416578 A GEAP202416578 A GE AP202416578A GE AP202416578 A GEAP202416578 A GE AP202416578A GE AP2024016578 A GEAP2024016578 A GE AP2024016578A GE AP202416578 A GEAP202416578 A GE AP202416578A
Authority
GE
Georgia
Prior art keywords
weight loss
skeletal muscle
muscle mass
methods
preserving
Prior art date
Application number
GEAP202416578A
Other languages
English (en)
Georgian (ka)
Inventor
Francisco Portell
Diane Jorkasky
Shaharyar Khan
Original Assignee
Rivus Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rivus Pharmaceuticals Inc filed Critical Rivus Pharmaceuticals Inc
Publication of GEAP202416578A publication Critical patent/GEAP202416578A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
GEAP202416578A 2022-02-07 2023-02-06 Methods of weight loss and preserving skeletal muscle mass GEAP202416578A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263307506P 2022-02-07 2022-02-07
US202263382456P 2022-11-04 2022-11-04

Publications (1)

Publication Number Publication Date
GEAP202416578A true GEAP202416578A (en) 2024-11-11

Family

ID=85556813

Family Applications (1)

Application Number Title Priority Date Filing Date
GEAP202416578A GEAP202416578A (en) 2022-02-07 2023-02-06 Methods of weight loss and preserving skeletal muscle mass

Country Status (12)

Country Link
US (1) US20250134864A1 (https=)
EP (1) EP4475841A1 (https=)
JP (1) JP2025505187A (https=)
KR (1) KR20240146052A (https=)
AU (1) AU2023216366A1 (https=)
CA (1) CA3243640A1 (https=)
CL (1) CL2024002341A1 (https=)
GE (1) GEAP202416578A (https=)
IL (1) IL314684A (https=)
JO (1) JOP20240177A1 (https=)
MX (1) MX2024009646A (https=)
WO (1) WO2023150767A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025199516A1 (en) * 2024-03-22 2025-09-25 Board Of Regents, The University Of Texas System Compositions and methods for preserving or increasing lean muscle mass

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3565806T (pt) 2017-01-06 2022-05-19 Rivus Pharmaceuticals Inc Novos derivados de fenilo

Also Published As

Publication number Publication date
US20250134864A1 (en) 2025-05-01
CA3243640A1 (en) 2023-08-10
JOP20240177A1 (ar) 2024-08-04
WO2023150767A1 (en) 2023-08-10
EP4475841A1 (en) 2024-12-18
IL314684A (en) 2024-10-01
CL2024002341A1 (es) 2025-01-17
KR20240146052A (ko) 2024-10-07
MX2024009646A (es) 2024-11-08
AU2023216366A1 (en) 2024-08-15
JP2025505187A (ja) 2025-02-21

Similar Documents

Publication Publication Date Title
CO2019014455A2 (es) Amidas heterocíclicas de 5 miembros y bicíclicas como inhibidores de rock
EP3816163A4 (en) CELL NECROSIS INHIBITORS, METHOD OF MANUFACTURE THEREOF AND USE THEREOF
KR102545148B9 (ko) 형광염색을 이용한 미세플라스틱의 질량추정방법
JOP20240177A1 (ar) طرق إنقاص الوزن والحفاظ على كتلة العضلات الهيكلية
IL286654A (en) A method for treating mastitis in cattle
MX2022000742A (es) Metodo para disminuir los efectos adversos del interferon.
EA201991570A1 (ru) Амидные соединения и их применение
IL307274A (en) Substituted 1-aryl-1'-heteroaryl compounds, substituted 1,1'-biheteroaryl compounds, and methods using same
IL287672A (en) A method for predicting the effectiveness of hemoglobinopathy treatment
ZA202104948B (en) Methods for obtaining induced smooth muscle cells
MX2026001345A (es) Composiciones y metodos para aumentar el peso corporal y la masa muscular magra mediante el uso de antagonistas contra el receptor de leptina, gdf8 y activina a
MX2025014322A (es) Metodos, composiciones y dispositivos para el aislamiento y analisis de expresion de regiones de interes de un tejido
GB202214331D0 (en) Balancing simulation mass, apparatus and associated methods
IL287037A (en) Method and apparatus for reconditioning organs
EP4119655A4 (en) YARROWIA SP VARIANT. AND METHOD FOR PREPARING FAT USING THE SAME
GB202111783D0 (en) Unicondylar balancer and method
PL4029992T3 (pl) Wykańczarka i sposób przestawiania skoku ubijaka
EP4028625B8 (en) Method of planning and/or performing an offshore well operation
MX2021013609A (es) Materiales y métodos para tratar la degeneración macular relacionada con la edad.
EA202190045A1 (ru) Составы/композиции, содержащие ибрутиниб
MX2023007919A (es) Injertos de tejido amniotico y metodos para preparar y usar los mismos.
EP4019549C0 (en) METHOD FOR ENRICHING CARDIAC MYOCYTES
IL289680A (en) Preparations and methods for tissue preservation for transplantation
DK3885484T3 (da) Fremgangsmåde til at gribe fat i tekstilgenstande
EP4051044A4 (en) COMPOSITIONS AND METHODS FOR MANUFACTURING SHOE STIFFENER